3d06 › Citations

Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.

Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z
J Mol Biol 385 249-65 (2009)
Related entries: 3d05, 3d07, 3d08, 3d09, 3d0a

Cited: 44 times
EuropePMC logo PMID: 18996393

Abstract

The tumor suppressor protein p53 is mutated in more than 50% of invasive cancers. About 30% of the mutations are found in six major "hot spot" codons located in its DNA binding core domain. To gain structural insight into the deleterious effects of such mutations and their rescue by suppressor mutations, we determined the crystal structures of the p53 core domain incorporating the hot spot mutation R249S, the core domain incorporating R249S and a second-site suppressor mutation H168R (referred to as the double mutant R249S/H168R) and its sequence-specific complex with DNA and of the triple mutant R249S/H168R/T123A. The structural studies were accompanied by transactivation and apoptosis experiments. The crystal structures show that the region at the vicinity of the mutation site in the R249S mutant displays a range of conformations [wild-type (wt) and several mutant-type conformations] due to the loss of stabilizing interactions mediated by R249 in the wt protein. As a consequence, the protein surface that is critical to the formation of functional p53-DNA complexes, through protein-protein and protein-DNA interactions, is largely distorted in the mutant conformations, thus explaining the protein's "loss of function" as a transcription factor. The structure of this region is restored in both R249S/H168R and R249S/H168R/T123A and is further stabilized in the complex of R249S/H168R with DNA. Our functional data show that the introduction of H168R as a second-site suppressor mutation partially restores the transactivation capacity of the protein and that this effect is further amplified by the addition of a third-site mutation T123A. These findings together with previously reported data on wt and mutant p53 provide a structural framework for understanding p53 dysfunction as a result of oncogenic mutations and its rescue by suppressor mutations and for a potential drug design aimed at restoring wt activity to aberrant p53 proteins.

Articles - 3d06 mentioned but not cited (9)

  1. Human germline and pan-cancer variomes and their distinct functional profiles. Pan Y, Karagiannis K, Zhang H, Dingerdissen H, Shamsaddini A, Wan Q, Simonyan V, Mazumder R. Nucleic Acids Res 42 11570-11588 (2014)
  2. Predicted molecular targets and pathways for germacrone, curdione, and furanodiene in the treatment of breast cancer using a bioinformatics approach. Kong Q, Ma Y, Yu J, Chen X. Sci Rep 7 15543 (2017)
  3. Highly precise protein-protein interaction prediction based on consensus between template-based and de novo docking methods. Ohue M, Matsuzaki Y, Shimoda T, Ishida T, Akiyama Y. BMC Proc 7 S6 (2013)
  4. Local conformational changes in the DNA interfaces of proteins. Sunami T, Kono H. PLoS One 8 e56080 (2013)
  5. Tumorigenic p53 mutants undergo common structural disruptions including conversion to α-sheet structure. Bromley D, Daggett V. Protein Sci 29 1983-1999 (2020)
  6. A systematic study of traditional Chinese medicine treating hepatitis B virus-related hepatocellular carcinoma based on target-driven reverse network pharmacology. Yin X, Li J, Hao Z, Ding R, Qiao Y. Front Cell Infect Microbiol 12 964469 (2022)
  7. The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins. Chakraborty S, Rendón-Ramírez A, Ásgeirsson B, Dutta M, Ghosh AS, Oda M, Venkatramani R, Rao BJ, Dandekar AM, Goñi FM. F1000Res 2 286 (2013)
  8. Molecular mechanism of Ruxian Shuhou prescription in the treatment of triple-negative breast cancer based on network pharmacology. Chu M, Meng T, Zhou Y, Jin L, Dai Q, Ma L, Chen H. Medicine (Baltimore) 102 e34763 (2023)
  9. Network Pharmacology-Based Strategy to Investigate Pharmacological Mechanisms of the Drug Pair Astragalus-Angelica for Treatment of Male Infertility. Zhao F, Deng Y, Du G, Liu S, Guo J, Wang H, Chen Y, Wang F, Geng Q. Evid Based Complement Alternat Med 2021 8281506 (2021)


Reviews citing this publication (8)

  1. Mutant p53: one name, many proteins. Freed-Pastor WA, Prives C. Genes Dev 26 1268-1286 (2012)
  2. When mutants gain new powers: news from the mutant p53 field. Brosh R, Rotter V. Nat Rev Cancer 9 701-713 (2009)
  3. The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches. Joerger AC, Fersht AR. Annu Rev Biochem 85 375-404 (2016)
  4. Contribution of p53 to metastasis. Powell E, Piwnica-Worms D, Piwnica-Worms H. Cancer Discov 4 405-414 (2014)
  5. The tumor suppressor p53: from structures to drug discovery. Joerger AC, Fersht AR. Cold Spring Harb Perspect Biol 2 a000919 (2010)
  6. The Rich World of p53 DNA Binding Targets: The Role of DNA Structure. Brázda V, Fojta M. Int J Mol Sci 20 E5605 (2019)
  7. Structural and Drug Targeting Insights on Mutant p53. Gomes AS, Ramos H, Inga A, Sousa E, Saraiva L. Cancers (Basel) 13 3344 (2021)
  8. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Wang H, Guo M, Wei H, Chen Y. Signal Transduct Target Ther 8 92 (2023)

Articles citing this publication (27)

  1. Proteogenomic Characterization of Endometrial Carcinoma. Dou Y, Kawaler EA, Cui Zhou D, Gritsenko MA, Huang C, Blumenberg L, Karpova A, Petyuk VA, Savage SR, Satpathy S, Liu W, Wu Y, Tsai CF, Wen B, Li Z, Cao S, Moon J, Shi Z, Cornwell M, Wyczalkowski MA, Chu RK, Vasaikar S, Zhou H, Gao Q, Moore RJ, Li K, Sethuraman S, Monroe ME, Zhao R, Heiman D, Krug K, Clauser K, Kothadia R, Maruvka Y, Pico AR, Oliphant AE, Hoskins EL, Pugh SL, Beecroft SJI, Adams DW, Jarman JC, Kong A, Chang HY, Reva B, Liao Y, Rykunov D, Colaprico A, Chen XS, Czekański A, Jędryka M, Matkowski R, Wiznerowicz M, Hiltke T, Boja E, Kinsinger CR, Mesri M, Robles AI, Rodriguez H, Mutch D, Fuh K, Ellis MJ, DeLair D, Thiagarajan M, Mani DR, Getz G, Noble M, Nesvizhskii AI, Wang P, Anderson ML, Levine DA, Smith RD, Payne SH, Ruggles KV, Rodland KD, Ding L, Zhang B, Liu T, Fenyö D, Clinical Proteomic Tumor Analysis Consortium. Cell 180 729-748.e26 (2020)
  2. Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs. Kitayner M, Rozenberg H, Rohs R, Suad O, Rabinovich D, Honig B, Shakked Z. Nat Struct Mol Biol 17 423-429 (2010)
  3. 30 years and a long way into p53 research. Hainaut P, Wiman KG. Lancet Oncol 10 913-919 (2009)
  4. Structural studies of p53 inactivation by DNA-contact mutations and its rescue by suppressor mutations via alternative protein-DNA interactions. Eldar A, Rozenberg H, Diskin-Posner Y, Rohs R, Shakked Z. Nucleic Acids Res 41 8748-8759 (2013)
  5. SPATA18, a spermatogenesis-associated gene, is a novel transcriptional target of p53 and p63. Bornstein C, Brosh R, Molchadsky A, Madar S, Kogan-Sakin I, Goldstein I, Chakravarti D, Flores ER, Goldfinger N, Sarig R, Rotter V. Mol Cell Biol 31 1679-1689 (2011)
  6. Functional plasticity and evolutionary adaptation of allosteric regulation. Leander M, Yuan Y, Meger A, Cui Q, Raman S. Proc Natl Acad Sci U S A 117 25445-25454 (2020)
  7. Effects of temperature on the p53-DNA binding interactions and their dynamical behavior: comparing the wild type to the R248Q mutant. Barakat K, Issack BB, Stepanova M, Tuszynski J. PLoS One 6 e27651 (2011)
  8. Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights. Merabet A, Houlleberghs H, Maclagan K, Akanho E, Bui TT, Pagano B, Drake AF, Fraternali F, Nikolova PV. Biochem J 427 225-236 (2010)
  9. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ). Degtjarik O, Golovenko D, Diskin-Posner Y, Abrahmsén L, Rozenberg H, Shakked Z. Nat Commun 12 7057 (2021)
  10. Structural Basis for p53 Lys120-Acetylation-Dependent DNA-Binding Mode. Vainer R, Cohen S, Shahar A, Zarivach R, Arbely E. J Mol Biol 428 3013-3025 (2016)
  11. Cooperativity dominates the genomic organization of p53-response elements: a mechanistic view. Pan Y, Nussinov R. PLoS Comput Biol 5 e1000448 (2009)
  12. Stochastic and Deterministic Models of Cellular p53 Regulation. Leenders GB, Tuszynski JA. Front Oncol 3 64 (2013)
  13. Detection of TP53 R249 Mutation in Iranian Patients with Pancreatic Cancer. Mohamadkhani A, Naderi E, Sharafkhah M, Fazli HR, Moradzadeh M, Pourshams A. J Oncol 2013 738915 (2013)
  14. Evaluating Drosophila p53 as a model system for studying cancer mutations. Herzog G, Joerger AC, Shmueli MD, Fersht AR, Gazit E, Segal D. J Biol Chem 287 44330-44337 (2012)
  15. Tracing the protectors path from the germ line to the genome. Coutandin D, Ou HD, Löhr F, Dötsch V. Proc Natl Acad Sci U S A 107 15318-15325 (2010)
  16. Dipeptide analysis of p53 mutations and evolution of p53 family proteins. Huang Q, Yu L, Levine AJ, Nussinov R, Ma B. Biochim Biophys Acta 1844 198-206 (2014)
  17. Lysine120 interactions with p53 response elements can allosterically direct p53 organization. Pan Y, Nussinov R. PLoS Comput Biol 6 e1000878 (2010)
  18. The Crystal Structure of the R280K Mutant of Human p53 Explains the Loss of DNA Binding. Gomes AS, Trovão F, Andrade Pinheiro B, Freire F, Gomes S, Oliveira C, Domingues L, Romão MJ, Saraiva L, Carvalho AL. Int J Mol Sci 19 E1184 (2018)
  19. Rescue of deleterious mutations by the compensatory Y30F mutation in ketosteroid isomerase. Cha HJ, Jang DS, Kim YG, Hong BH, Woo JS, Kim KT, Choi KY. Mol Cells 36 39-46 (2013)
  20. Investigating DNA Binding and Conformational Variation in Temperature Sensitive p53 Cancer Mutants Using QM-MM Simulations. Koulgi S, Achalere A, Sonavane U, Joshi R. PLoS One 10 e0143065 (2015)
  21. p53 R175H hydrophobic patch and H-bond reorganization observed by MD simulation. Thayer KM, Quinn TR. Biopolymers 105 176-185 (2016)
  22. Comparative Study Mutantelec: An In Silico mutation simulation platform for comparative electrostatic potential profiling of proteins. Valdebenito-Maturana B, Reyes-Suarez JA, Henriquez J, Holmes DS, Quatrini R, Pohl E, Arenas-Salinas M. J Comput Chem 38 467-474 (2017)
  23. QM-MM simulations on p53-DNA complex: a study of hot spot and rescue mutants. Koulgi S, Achalere A, Sharma N, Sonavane U, Joshi R. J Mol Model 19 5545-5559 (2013)
  24. Chemical principles additive model aligns low consensus DNA targets of p53 tumor suppressor protein. Thayer KM, Han ISM. Comput Biol Chem 68 186-193 (2017)
  25. Tanshinone IIA promotes apoptosis by downregulating BCL2 and upregulating TP53 in triple-negative breast cancer. Liu J, Zhang C, Liu S, Wang X, Wu X, Hao J. Naunyn Schmiedebergs Arch Pharmacol 396 365-374 (2023)
  26. p53: balancing tumour suppression and implications for the clinic. Buganim Y, Rotter V. Eur J Cancer 45 Suppl 1 217-234 (2009)
  27. A cytosolic mutp53(E285K) variant confers chemoresistance of malignant melanoma. Dunsche L, Ivanisenko N, Riemann S, Schindler S, Beissert S, Angeli C, Kreis S, Tavassoli M, Lavrik I, Kulms D. Cell Death Dis 14 831 (2023)


Quick links